News & Events
CEO Gary Glick Talks STING with Chemical & Engineering News
IFM Therapeutics CEO Gary Glick was recently interviewed by Chemical and Engineering News (C&EN) as part of a story on the STING pathway. In the article, Glick spoke about how targeting the innate immune system can provide the “spark” to make existing cancer immunotherapies more effective. The article also highlights the interest in developing antagonists of STING for autoimmune disorders.
View the full story, “STING fever is sweeping through the cancer immunotherapy world” on C&EN.